504 related articles for article (PubMed ID: 31122893)
21. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
[TBL] [Abstract][Full Text] [Related]
22. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).
Costabel U; Albera C; Lancaster LH; Lin CY; Hormel P; Hulter HN; Noble PW
Respiration; 2017; 94(5):408-415. PubMed ID: 28898890
[TBL] [Abstract][Full Text] [Related]
23. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE; Bradford WZ; Castro-Bernardini S; Fagan EA; Glaspole I; Glassberg MK; Gorina E; Hopkins PM; Kardatzke D; Lancaster L; Lederer DJ; Nathan SD; Pereira CA; Sahn SA; Sussman R; Swigris JJ; Noble PW;
N Engl J Med; 2014 May; 370(22):2083-92. PubMed ID: 24836312
[TBL] [Abstract][Full Text] [Related]
24. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
25. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis.
Jouneau S; Crestani B; Thibault R; Lederlin M; Vernhet L; Valenzuela C; Wijsenbeek M; Kreuter M; Stansen W; Quaresma M; Cottin V
Respir Res; 2020 Nov; 21(1):312. PubMed ID: 33239000
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
Richeldi L; Kolb M; Jouneau S; Wuyts WA; Schinzel B; Stowasser S; Quaresma M; Raghu G
BMC Pulm Med; 2020 Jan; 20(1):3. PubMed ID: 31914963
[TBL] [Abstract][Full Text] [Related]
27. Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON.
Song JW; Ogura T; Inoue Y; Xu Z; Quaresma M; Stowasser S; Stansen W; Crestani B
Respirology; 2020 Apr; 25(4):410-416. PubMed ID: 31329360
[TBL] [Abstract][Full Text] [Related]
28. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
30. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.
Maher TM; van der Aar EM; Van de Steen O; Allamassey L; Desrivot J; Dupont S; Fagard L; Ford P; Fieuw A; Wuyts W
Lancet Respir Med; 2018 Aug; 6(8):627-635. PubMed ID: 29792287
[TBL] [Abstract][Full Text] [Related]
31. First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.
Wuyts WA; Kolb M; Stowasser S; Stansen W; Huggins JT; Raghu G
Lung; 2016 Oct; 194(5):739-43. PubMed ID: 27377558
[TBL] [Abstract][Full Text] [Related]
32. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.
Nathan SD; Behr J; Collard HR; Cottin V; Hoeper MM; Martinez FJ; Corte TJ; Keogh AM; Leuchte H; Mogulkoc N; Ulrich S; Wuyts WA; Yao Z; Boateng F; Wells AU
Lancet Respir Med; 2019 Sep; 7(9):780-790. PubMed ID: 31416769
[TBL] [Abstract][Full Text] [Related]
33. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
[TBL] [Abstract][Full Text] [Related]
34. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
[TBL] [Abstract][Full Text] [Related]
35. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial.
Raghu G; Pellegrini CA; Yow E; Flaherty KR; Meyer K; Noth I; Scholand MB; Cello J; Ho LA; Pipavath S; Lee JS; Lin J; Maloney J; Martinez FJ; Morrow E; Patti MG; Rogers S; Wolters PJ; Yates R; Anstrom KJ; Collard HR
Lancet Respir Med; 2018 Sep; 6(9):707-714. PubMed ID: 30100404
[TBL] [Abstract][Full Text] [Related]
36. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
Kreuter M; Wuyts WA; Wijsenbeek M; Bajwah S; Maher TM; Stowasser S; Male N; Stansen W; Schoof N; Orsatti L; Swigris J
Respir Res; 2020 Jan; 21(1):36. PubMed ID: 32000772
[TBL] [Abstract][Full Text] [Related]
37. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.
Lancaster L; Crestani B; Hernandez P; Inoue Y; Wachtlin D; Loaiza L; Quaresma M; Stowasser S; Richeldi L
BMJ Open Respir Res; 2019; 6(1):e000397. PubMed ID: 31179001
[TBL] [Abstract][Full Text] [Related]
38. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability.
Nambiar A; Kellogg D; Justice J; Goros M; Gelfond J; Pascual R; Hashmi S; Masternak M; Prata L; LeBrasseur N; Limper A; Kritchevsky S; Musi N; Tchkonia T; Kirkland J
EBioMedicine; 2023 Apr; 90():104481. PubMed ID: 36857968
[TBL] [Abstract][Full Text] [Related]
39. Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis.
Flaherty KR; Kolb M; Vancheri C; Tang W; Conoscenti CS; Richeldi L
Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946007
[TBL] [Abstract][Full Text] [Related]
40. Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis.
Nathan SD; Behr J; Cottin V; Lancaster L; Smith P; Deng CQ; Pearce N; Bell H; Peterson L; Flaherty KR
BMJ Open Respir Res; 2022 Jul; 9(1):. PubMed ID: 35787522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
